Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2026 08:05 ET | Source: Century Therapeutics, Inc.

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1...
October 02, 2026 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market...
October 02, 2026 08:05 ET | Source: Autonomix Medical, Inc.

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall ...
October 02, 2026 08:05 ET | Source: Integra LifeSciences Holdings Corporation

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary...
October 02, 2026 08:05 ET | Source: Ethos Aesthetics + Wellness

Hudson County Botox Listings Leave a 51.7-Point After-Work Hours Gap

HOBOKEN, NJ, Oct. 02, 2026 (GLOBE NEWSWIRE) -- For many people in Hudson County, the only realistic time for a Botox consultation is after the workday ends. The listings tell a different story. A...
October 02, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients

The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that...
October 02, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipamAn interim 18-month analysis of an ongoing open-label...
October 02, 2026 08:00 ET | Source: Hyperion DeFi, Inc.

Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced it has repurchased 240,124 HYPD common shares at a weighted average...
October 02, 2026 08:00 ET | Source: Volaris Group Inc

Teknisa Joins Volaris Group

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Volaris Group announced today the acquisition of Teknisa, a provider of software solutions for the corporate foodservice and retail vertical. With 36...
October 02, 2026 08:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus...